Mode
Text Size
Log in / Sign up
N/A N=110

Cognition and Psychotherapy in PTSD

Posttraumatic Stress Disorder (PTSD)

Enrolled (actual)
110
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Change in PTSD Checklist (PCL-5) — 9.25; 11.94; 15.91 change in units on a scale

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Cognitive Processing Therapy (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Sep 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in PTSD Checklist (PCL-5)
9.25; 11.94; 15.91
PRIMARY
Social Adjustment Scale-Self Report (SAS-SR)
0.14; 0.10; 0.38
SECONDARY
Veterans RAND 12 Item Health Survey Mental Component Summary (VR-12 MCS)
1.26; 0.32; 0.39

Summary

Posttraumatic stress disorder (PTSD) is prevalent among combat Veterans and is a substantial public health burden. Several psychotherapies, including cognitive processing therapy (CPT) and prolonged exposure therapy, have been recommended as efficacious for the treatment of PTSD and are being disseminated nationally in the VA Healthcare System. Yet many individuals show limited benefit from such treatments. Accumulating evidence indicates that episodic memory deficits may be one factor limiting psychotherapy treatment efficacy in PTSD. The proposed study will determine whether verbal memory is a specific predictor of CPT outcomes in PTSD, including both symptom reductions and functional outcomes. The study will also determine the pathways by which memory functioning affects treatment outcomes by examining relationships between memory functioning, treatment engagement, recall of treatment content, and illness course. More specifically, analyses will examine whether memory for treatment content affects the relationship between memory functioning and treatment outcomes.

Eligibility Criteria

Inclusion Criteria

  • DSM-5 criteria for PTSD via the Clinician Administered PTSD Scale (CAPS-5)
  • Willing to initiate CPT

Exclusion Criteria

  • Substance use disorder (moderate or above) not in remission for >1 mo
  • Severe psychiatric illness (e.g., psychosis)
  • Significant current suicidal or homicidal intent, including a specific plan
  • Dementia, neurological disorder, or severe traumatic brain injury (TBI; i.e., loss of consciousness > 24h)
  • Inability to speak or read English
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03641924). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search